TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20616321

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 612

Group type: COMPARATOR
Intervention: Neurosurgery
Number of subjects: 612
Study: 18416404

Group type: EXPERIMENTAL
Intervention: Early parenting intervention
Number of subjects: 185
Study: 16869994

Group type: EXPERIMENTAL
Intervention: Fermented gruel with live L. plantarum 299v
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pasteurised fermented gruel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-fermented gruel with added organic acids
Number of subjects: 24

Group type: COMPARATOR
Intervention: pH-adjusted non-fermented gruel
Number of subjects: 24
Study: 12616127

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO) 300 IU/kg body weight plus 100 mg iron intravenously
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo medication and iron
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 63
Study: 10688215

Group type: EXPERIMENTAL
Intervention: Barium and sodium diatrizoate (Gastrografin) (n = 48)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no contrast) (n = 50)
Number of subjects: 98
Study: 9499605

Group type: EXPERIMENTAL
Intervention: 2% zinc sulphate
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 7% sodium chloride
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pentavalent antimony compound (sodium stibogluconate)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 63
Study: 8372752

Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3793333

Group type: EXPERIMENTAL
Intervention: nifedipine (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: diltiazem (60 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: verapamil (80 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 29220542

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 250

Group type: COMPARATOR
Intervention: Etanercept 50 mg QW
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 28408729

Group type: EXPERIMENTAL
Intervention: Menatetrenone and risedronate plus calcium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24461794

Group type: EXPERIMENTAL
Intervention: Skimmed milk
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 193

Group type: COMPARATOR
Intervention: Water
Number of subjects: 193

Group type: COMPARATOR
Intervention: Pre-test control group
Number of subjects: 193
Study: 22446676

Group type: EXPERIMENTAL
Intervention: Video and verbal feedback (Intervention Group, IG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No feedback (Control Group, CG)
Number of subjects: 19
Study: 20959578

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d)
Number of subjects: 16608

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 18063394

Group type: EXPERIMENTAL
Intervention: Patients with TnI elevation (20 patients, 47%)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Patients without TnI elevation (23 patients, 53%)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: TnI elevation as an independent predictor
Number of subjects: 43
Study: 15910557

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (RSV)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Atorvastatin (ATV)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 263
Study: 12579625

Group type: EXPERIMENTAL
Intervention: Revised Urogenital Distress Inventory (UDI)
Number of subjects: 2238

Group type: EXPERIMENTAL
Intervention: Revised Incontinence Impact Questionnaire (IIQ)
Number of subjects: 2238

Group type: EXPERIMENTAL
Intervention: Criterion and construct validity tests of UDI and IIQ subscales
Number of subjects: 2238
Study: 10473054

Group type: EXPERIMENTAL
Intervention: hCRH (1 microg/kg/h in saline) infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 8697744

Group type: EXPERIMENTAL
Intervention: Bilateral presentation of letter pairs (verbal matching task)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bilateral presentation of dot pattern pairs (nonverbal matching task)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Unilateral presentation of letter pairs (verbal matching task)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Unilateral presentation of dot pattern pairs (nonverbal matching task)
Number of subjects: 27
Study: 1753737

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (40 minutes including warm-up and cool-down)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Autogenic relaxation (30 minutes listening to instructions)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (excused after anxiety induction)
Number of subjects: 85
Study: 6138053

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30917691

Group type: EXPERIMENTAL
Intervention: OneTouch Reveal® diabetes app with telemedical features
Number of subjects: 5
Study: 29741923

Group type: EXPERIMENTAL
Intervention: PRP treatment (n = 27)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham treatment (n = 23)
Number of subjects: 50
Study: 29231359

Group type: EXPERIMENTAL
Intervention: Acupoint pressure therapy applied at uterine orifice dilation of 2 to 3 cm, 5 to 6 cm, 7 to 8 cm, and 9 to 10 cm.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupoint pressure therapy (observation group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no acupoint pressure therapy)
Number of subjects: 120
Study: 24597699

Group type: EXPERIMENTAL
Intervention: Locked Volar Plate (VP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: External Fixator (EF)
Number of subjects: 72
Study: 21947244

Group type: COMPARATOR
Intervention: Coiling without DCI
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Coiling with DCI
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Clipping without DCI
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Clipping with DCI
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Clipping and DCI
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Coiling and DCI (for patients treated within 4 days)
Number of subjects: 2143
Study: 19908346

Group type: EXPERIMENTAL
Intervention: Gastrectomy plus splenectomy
Number of subjects: 466
Study: 17262713

Group type: EXPERIMENTAL
Intervention: Hyperosmolar gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Iso-osmolar gel
Number of subjects: 10
Study: 15274066

Group type: COMPARATOR
Intervention: Subcutaneous interferon-alpha (9 MU daily) - Arm A
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon-alpha (9 MU daily) plus oral 13-cis retinoic acid (1 mg/kg) - Arm B
Number of subjects: 103
Study: 12471281

Group type: EXPERIMENTAL
Intervention: Nasal packing with an airway (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nasal packing without an airway (n=20)
Number of subjects: 40
Study: 10234421

Group type: EXPERIMENTAL
Intervention: Public performance condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Private performance condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diastolic pressure responses
Number of subjects: 0
Study: 7708179

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2667865

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (sCT) 100 U injected subcutaneously every second day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 36
Study: 145230

Group type: EXPERIMENTAL
Intervention: Pentobarbitone i.v.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Droperidol i.v.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pentobarbitone
Number of subjects: 135

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 135

Group type: COMPARATOR
Intervention: Pentobarbitone or Droperidol
Number of subjects: 135
Study: 30765033

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 150
Study: 28069970

Group type: EXPERIMENTAL
Intervention: Welding employment (≥1 year)
Number of subjects: 53454

Group type: EXPERIMENTAL
Intervention: Foundry work employment (≥1 year)
Number of subjects: 53454

Group type: EXPERIMENTAL
Intervention: Joint employment in welding and foundry work (≥1 year)
Number of subjects: 53454

Group type: EXPERIMENTAL
Intervention: Increasing years of employment in welding
Number of subjects: 53454

Group type: EXPERIMENTAL
Intervention: Increasing years of employment in foundry work
Number of subjects: 53454
Study: 25799356

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) system at 30 L/minute
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) system at 50 L/minute
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oxygen at 5 L/minute through a nasal cannula (NC5 group)
Number of subjects: 30
Study: 24195548

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) plus abacavir-lamivudine once daily (DTG-ABC-3TC group)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Combination therapy with efavirenz-tenofovir disoproxil fumarate-emtricitabine once daily (EFV-TDF-FTC group)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus abacavir-lamivudine
Number of subjects: 833

Group type: COMPARATOR
Intervention: efavirenz-tenofovir disoproxil fumarate-emtricitabine
Number of subjects: 833
Study: 21165629

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Diet (HC; 60% carbohydrate, 20% fat, 20% protein)
Number of subjects: 18

Group type: COMPARATOR
Intervention: High-Fat Diet (HF; 50% fat, 30% carbohydrate, 20% protein)
Number of subjects: 18

Group type: COMPARATOR
Intervention: High-Carbohydrate Diet (HC) vs High-Fat Diet (HF)
Number of subjects: 18
Study: 19682096

Group type: EXPERIMENTAL
Intervention: Dental treatment under a comprehensive dental programme
Number of subjects: 139
Study: 17655888

Group type: EXPERIMENTAL
Intervention: Dried-bonito broth
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15656462

Group type: EXPERIMENTAL
Intervention: OpSite Post‐Op
Number of subjects: 300

Group type: COMPARATOR
Intervention: Tegaderm with pad
Number of subjects: 300

Group type: COMPARATOR
Intervention: Primapore
Number of subjects: 300
Study: 12384264

Group type: EXPERIMENTAL
Intervention: Enbucrilate tissue adhesive
Number of subjects: 62

Group type: COMPARATOR
Intervention: Subcuticular polyglycolic acid sutures
Number of subjects: 62
Study: 9869105

Group type: EXPERIMENTAL
Intervention: High-dose Epirubicin (EPI) 120 mg/m2 plus Cisplatin (CP) 60 mg/m2
Number of subjects: 228

Group type: COMPARATOR
Intervention: Vinorelbine (VNR) 25 mg/m2 plus Cisplatin (CP) 60 mg/m2
Number of subjects: 228
Study: 7657856

Group type: EXPERIMENTAL
Intervention: Cimetidine (1600 mg per day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Famotidine (80 mg per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2621066

Group type: EXPERIMENTAL
Intervention: St. Thomas' hospital solution (potassium concentration 20 mmol/l) - group A
Number of subjects: 163

Group type: COMPARATOR
Intervention: Ringer's injection (potassium concentration 4 mmol/l) - group B
Number of subjects: 163
Study: 4834097

Group type: EXPERIMENTAL
Intervention: Induction dose of methohexitone 1.0 mg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Induction dose of methohexitone 1.4 mg/kg
Number of subjects: 26
Study: 31548678

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28667230

Group type: EXPERIMENTAL
Intervention: Combination povidone iodine and sodium fluoride dental varnish
Number of subjects: 284

Group type: COMPARATOR
Intervention: Sodium fluoride dental varnish
Number of subjects: 284
Study: 25692251

Group type: EXPERIMENTAL
Intervention: Intrathoracic pressure regulation (ITPR, -12 cm H2O vacuum)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intrathoracic pressure regulation (ITPR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (device but no vacuum)
Number of subjects: 7
Study: 24330505

Group type: EXPERIMENTAL
Intervention: Climate Schools intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21762878

Group type: EXPERIMENTAL
Intervention: high-frequency (10 Hz) rTMS directed at the SFG
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: low-frequency (1 Hz) rTMS directed at the SFG
Number of subjects: 15

Group type: COMPARATOR
Intervention: low-frequency (1 Hz) rTMS directed at the motor cortex
Number of subjects: 15
Study: 19154844

Group type: EXPERIMENTAL
Intervention: Sauna bathing program (3 times a week for 4 weeks at 60±1 degrees C, 15-20 minutes per session)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sauna bathing program
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (usual activities and medications)
Number of subjects: 9
Study: 15650512

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 168
Study: 10078849

Group type: EXPERIMENTAL
Intervention: exercise/energy balance (EI=EE=15.1+/‐0.6 MJ)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: exercise/negative energy balance (EI=11.8+/‐0.8 MJ, EE=15.1+/‐0.8 MJ)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: exercise/positive energy balance (EI=18.6+/‐0.7 MJ, EE=15.1+/‐0.6 MJ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: no exercise/energy balance (EI=EE=11.8+/‐0.8 MJ)
Number of subjects: 8
Study: 7594512

Group type: EXPERIMENTAL
Intervention: Low dose TNFR:Fc (10 mg/m2 i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High dose TNFR:Fc (60 mg/m2 i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TNFR:Fc (both doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2299797

Group type: EXPERIMENTAL
Intervention: Long-term hemodialysis (HD) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First dialysis session in uremic (UR) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dialysis session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dialysis membrane (CUP or PAN-AN 69)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term HD patients
Number of subjects: 0
Study: 7033351

Group type: EXPERIMENTAL
Intervention: Sucralfate (500 mg tablets, two tablets after meals and at bedtime)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo (tablets after meals and at bedtime)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Laboratory tests
Number of subjects: 216
Study: 28803925

Group type: EXPERIMENTAL
Intervention: Swedish screening protocol (2-year interval, PSA cut-off 3.0 ng/ml)
Number of subjects: 31967

Group type: EXPERIMENTAL
Intervention: Lower PSA threshold in Finland (PSA cut-off <4.0 ng/ml)
Number of subjects: 31967

Group type: COMPARATOR
Intervention: Finnish screening protocol (4-year interval, PSA cut-off 4.0 ng/ml)
Number of subjects: 31967
Study: 29048238

Group type: EXPERIMENTAL
Intervention: Vitamin B12-containing ointment (M-treatment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glycerol-petrolatum-based emollient cream (C-treatment)
Number of subjects: 24
Study: 24284689

Group type: EXPERIMENTAL
Intervention: fixed split‐angle keyboard
Number of subjects: 77

Group type: COMPARATOR
Intervention: standard flat keyboard
Number of subjects: 77
Study: 24226805

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted catheter-directed thrombolysis (USAT) with 10 to 20 mg recombinant tissue plasminogen activator over 15 hours
Number of subjects: 59

Group type: COMPARATOR
Intervention: Unfractionated heparin alone (heparin group)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Safety outcomes for both groups
Number of subjects: 59
Study: 21493314

Group type: EXPERIMENTAL
Intervention: Cold saline-soaked gauze compression
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dry gauze compression
Number of subjects: 300
Study: 17918146

Group type: EXPERIMENTAL
Intervention: GeneVac-B
Number of subjects: 20

Group type: COMPARATOR
Intervention: Engerix-B
Number of subjects: 20
Study: 15553819

Group type: EXPERIMENTAL
Intervention: Oxygen and TFM (tongfei mixture)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 11489102

Group type: EXPERIMENTAL
Intervention: Systematic patient feedback intervention
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no patient feedback)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Second intervention group (model of patient feedback)
Number of subjects: 210
Study: 9732218

Group type: EXPERIMENTAL
Intervention: Fadrozole
Number of subjects: 96

Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 96
Study: 8291919

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan) regimen A (100 mg/m2 weekly)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan) regimen C (200 mg/m2 every 3-4 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan) overall
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan)
Number of subjects: 25

Group type: COMPARATOR
Intervention: CPT-11 (irinotecan) regimen C vs regimen A
Number of subjects: 25
Study: 28591084

Group type: EXPERIMENTAL
Intervention: Local ketamine 1 mg/kg instilled in the wound
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine 1 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (10 mL normal saline instilled in the wound)
Number of subjects: 90
Study: 26371370

Group type: EXPERIMENTAL
Intervention: 5-mm umbilical port and laparoscope (5LH)
Number of subjects: 78

Group type: COMPARATOR
Intervention: 10-mm umbilical port and laparoscope (10LH)
Number of subjects: 78
Study: 25394438

Group type: EXPERIMENTAL
Intervention: Sodium (Na) bicarbonate infusion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) + Sodium Chloride (NaCl)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sodium Chloride (NaCl)
Number of subjects: 150
Study: 23383117

Group type: EXPERIMENTAL
Intervention: Clinical monitoring plus laboratory monitoring
Number of subjects: 459

Group type: COMPARATOR
Intervention: Clinical monitoring alone
Number of subjects: 459
Study: 20952003

Group type: EXPERIMENTAL
Intervention: 300 U botulinum toxin-A intradetrusor injections excluding the trigone (detrusor arm)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 200 U intradetrusor plus 100 U intratrigonal injections (combined arm)
Number of subjects: 36
Study: 19391536

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Yaoyangguan (GV 3), Dachangshu (BL 25), Guanyuanshu (BL 26), Xiaochangshu (BI. 27) plus blood-letting puncture at Weizhong (BL 40)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traction combined with electroacupuncture at Jiaji (EX-B 2), Shenshu (BL 23), Dachangshu (BL 25)
Number of subjects: 100
Study: 16805720

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study: 15460215

Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 25302

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 25302
Study: 11299091

Group type: EXPERIMENTAL
Intervention: Soybean protein intake (upper quartile: 8.7-35.2 g/day)
Number of subjects: 200
Study: 9161933

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 300
Study: 8203790

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (group D, n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (group P, n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (group D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 120
Study: 3441747

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) administration of 2 micrograms
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) administration of 20 micrograms
Number of subjects: 58

Group type: COMPARATOR
Intervention: Subcutaneous administration of 2 micrograms
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) and Intramuscular (i.m.) routes
Number of subjects: 58
Study: 29504671

Group type: EXPERIMENTAL
Intervention: HFNC 6 L/minute
Number of subjects: 21

Group type: COMPARATOR
Intervention: nCPAP 3 cmH2 O
Number of subjects: 21
Study: 27605403

Group type: EXPERIMENTAL
Intervention: AHEI (2010 Alternate Healthy Eating Index)
Number of subjects: 12406
Study: 24985962

Group type: EXPERIMENTAL
Intervention: Enzalutamide and abiraterone in combination with standard-of-care
Number of subjects: 0
Study: 23615395

Group type: EXPERIMENTAL
Intervention: Theobromine (0.0011 mol/l)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NaF toothpaste slurry (0.0789 mol/l F)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 30
Study: 19818785

Group type: EXPERIMENTAL
Intervention: Combination of immunosuppressive therapy (azathioprine) and 3 infusions of infliximab
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional corticosteroids
Number of subjects: 133
Study: 19027269

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Combination antipsychotic treatment
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 270